000143640 001__ 143640
000143640 005__ 20240229112601.0
000143640 0247_ $$2doi$$a10.1007/s00401-019-02021-z
000143640 0247_ $$2pmid$$apmid:31062076
000143640 0247_ $$2ISSN$$a0001-6322
000143640 0247_ $$2ISSN$$a1432-0533
000143640 0247_ $$2altmetric$$aaltmetric:60082153
000143640 037__ $$aDKFZ-2019-01217
000143640 041__ $$aeng
000143640 082__ $$a610
000143640 1001_ $$0P:(DE-He78)7f9dda5a1b9a9ffc384598e80ade05f9$$aWirthschaft, Peter$$b0$$eFirst author$$udkfz
000143640 245__ $$aRhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas.
000143640 260__ $$aHeidelberg$$bSpringer$$c2019
000143640 3367_ $$2DRIVER$$aarticle
000143640 3367_ $$2DataCite$$aOutput Types/Journal article
000143640 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1686741925_24958
000143640 3367_ $$2BibTeX$$aARTICLE
000143640 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143640 3367_ $$00$$2EndNote$$aJournal Article
000143640 520__ $$aGlioblastomas strongly invade the brain by infiltrating into the white matter along myelinated nerve fiber tracts even though the myelin protein Nogo-A prevents cell migration by activating inhibitory RhoA signaling. The mechanisms behind this long-known phenomenon remained elusive so far, precluding a targeted therapeutic intervention. This study demonstrates that the prevalent activation of AKT in gliomas increases the ER protein-folding capacity and enables tumor cells to utilize a side effect of RhoA activation: the perturbation of the IRE1α-mediated decay of SPARC mRNA. Once translation is initiated, glioblastoma cells rapidly secrete SPARC to block Nogo-A from inhibiting migration via RhoA. By advanced ultramicroscopy for studying single-cell invasion in whole, undissected mouse brains, we show that gliomas require SPARC for invading into white matter structures. SPARC depletion reduces tumor dissemination that significantly prolongs survival and improves response to cytostatic therapy. Our finding of a novel RhoA-IRE1 axis provides a druggable target for interfering with SPARC production and underscores its therapeutic value.
000143640 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000143640 588__ $$aDataset connected to CrossRef, PubMed,
000143640 7001_ $$0P:(DE-HGF)0$$aBode, Julia$$b1
000143640 7001_ $$0P:(DE-He78)34d5c41508d3317e721bfb593ef5948d$$aSoni, Himanshu$$b2$$udkfz
000143640 7001_ $$0P:(DE-He78)268bacdaa8869513e9bbb14f2b838ada$$aDietrich, Fabio$$b3$$udkfz
000143640 7001_ $$0P:(DE-He78)d9984bb7c7ce85fffd8c63899fb1d7fa$$aKrüwel, Thomas$$b4$$udkfz
000143640 7001_ $$0P:(DE-He78)5e8c9e37b2ec5e928b6170cf9ecf9770$$aFischer, Bernd$$b5$$udkfz
000143640 7001_ $$aKnobbe-Thomsen, Christiane B$$b6
000143640 7001_ $$aRossetti, Giulia$$b7
000143640 7001_ $$aHentschel, Andreas$$b8
000143640 7001_ $$0P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aMack, Norman$$b9$$udkfz
000143640 7001_ $$aSchönig, Kai$$b10
000143640 7001_ $$0P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aBreckwoldt, Michael O$$b11$$udkfz
000143640 7001_ $$aSchmandke, André$$b12
000143640 7001_ $$0P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aPusch, Stefan$$b13$$udkfz
000143640 7001_ $$aMedenbach, Jan$$b14
000143640 7001_ $$aBendszus, Martin$$b15
000143640 7001_ $$aSchwab, Martin E$$b16
000143640 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b17$$udkfz
000143640 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b18$$udkfz
000143640 7001_ $$aHerold-Mende, Christel$$b19
000143640 7001_ $$0P:(DE-HGF)0$$aReifenberger, Guido$$b20
000143640 7001_ $$aAhrends, Robert$$b21
000143640 7001_ $$0P:(DE-He78)a33ae52a1d80b847405db3ab83b9e90d$$aTews, Björn$$b22$$eLast author$$udkfz
000143640 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-019-02021-z$$n2$$p275-293$$tActa neuropathologica$$v138$$x1432-0533$$y2019
000143640 909CO $$ooai:inrepo02.dkfz.de:143640$$pVDB
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7f9dda5a1b9a9ffc384598e80ade05f9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34d5c41508d3317e721bfb593ef5948d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)268bacdaa8869513e9bbb14f2b838ada$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d9984bb7c7ce85fffd8c63899fb1d7fa$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5e8c9e37b2ec5e928b6170cf9ecf9770$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000143640 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a33ae52a1d80b847405db3ab83b9e90d$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000143640 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000143640 9141_ $$y2019
000143640 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143640 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2017
000143640 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143640 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143640 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143640 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143640 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143640 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143640 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143640 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143640 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143640 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143640 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143640 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bACTA NEUROPATHOL : 2017
000143640 9201_ $$0I:(DE-He78)V077-20160331$$kV077$$lAG Molekulare Mechanismen der Tumorzell-Invasion$$x0
000143640 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000143640 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x2
000143640 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000143640 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x4
000143640 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000143640 980__ $$ajournal
000143640 980__ $$aVDB
000143640 980__ $$aI:(DE-He78)V077-20160331
000143640 980__ $$aI:(DE-He78)B062-20160331
000143640 980__ $$aI:(DE-He78)D170-20160331
000143640 980__ $$aI:(DE-He78)B300-20160331
000143640 980__ $$aI:(DE-He78)L401-20160331
000143640 980__ $$aI:(DE-He78)L101-20160331
000143640 980__ $$aUNRESTRICTED